← Leaderboards
Ira Pastan
Basic Sciences
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Basic Sciences
Same institution · by research overlap
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMesothelinMesotheliomaImmunotoxinsTumorClinical TrialsCellsMalignant Neoplasm Of PancreasCollaborationsCd22 GeneMalignant Neoplasm Of OvarySolid NeoplasmMalignant Neoplasm Of LungHairy Cell LeukemiaImmunogenicityHematopoietic NeoplasmsImmunotoxin TherapyPreclinical StudyLymphomaResponseAntibodiesGrowthCancer CellBreast Neoplasms
Grant awards (85)
CAR-T Therapy of Mesothelin Expressing Cancers$1,518,034
ZIA · FY2025 · CA · contact PI
CAR-T Therapy of Mesothelin Expressing Cancers$2,387,218
ZIA · FY2024 · CA · contact PI
Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies$265,247
ZIA · FY2024 · CA · contact PI
CAR-T Therapy of Mesothelin Expressing Cancers$2,031,577
ZIA · FY2023 · CA · contact PI
Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies$725,564
ZIA · FY2023 · CA · contact PI
Growth Regulation Section$145,113
ZIA · FY2023 · CA · contact PI
CAR-T Therapy of Mesothelin Expressing Cancers$2,085,050
ZIA · FY2022 · CA · contact PI
Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies$868,770
ZIA · FY2022 · CA · contact PI
Clinical Trials with Immunotoxins$347,508
ZIA · FY2022 · CA · contact PI
Growth Regulation Section$173,754
ZIA · FY2022 · CA · contact PI
Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies$3,096,310
ZIA · FY2021 · CA · contact PI
Clinical Trials with Immunotoxins$364,272
ZIA · FY2021 · CA · contact PI
Growth Regulation Section$182,136
ZIA · FY2021 · CA · contact PI
Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies$2,122,084
ZIA · FY2020 · CA · contact PI
Clinical Trials with Immunotoxins$606,310
ZIA · FY2020 · CA · contact PI
Growth Regulation Section$303,154
ZIA · FY2020 · CA · contact PI
Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies$2,256,859
ZIA · FY2019 · CA · contact PI
Clinical Trials with Immunotoxins$644,817
ZIA · FY2019 · CA · contact PI
Growth Regulation Section$322,409
ZIA · FY2019 · CA · contact PI
Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies$2,356,009
ZIA · FY2018 · CA · contact PI
Clinical Trials with Immunotoxins$673,145
ZIA · FY2018 · CA · contact PI
Growth Regulation Section$336,573
ZIA · FY2018 · CA · contact PI
Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies$2,989,362
ZIA · FY2017 · CA · contact PI
Clinical Trials with Immunotoxins$854,104
ZIA · FY2017 · CA · contact PI
Growth Regulation Section$427,052
ZIA · FY2017 · CA · contact PI
Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies$2,418,418
ZIA · FY2016 · CA · contact PI
Clinical Trials with Immunotoxins$690,977
ZIA · FY2016 · CA · contact PI
Growth Regulation Section$345,488
ZIA · FY2016 · CA · contact PI
Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies$2,449,375
ZIA · FY2015 · CA · contact PI
Clinical Trials with Immunotoxins$1,029,447
ZIA · FY2015 · CA · contact PI
Growth Regulation Section$70,996
ZIA · FY2015 · CA · contact PI
Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies$2,511,684
ZIA · FY2014 · CA · contact PI
Clinical Trials with Immunotoxins$1,108,096
ZIA · FY2014 · CA · contact PI
Growth Regulation Section$73,873
ZIA · FY2014 · CA · contact PI
Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies$2,243,727
ZIA · FY2013 · CA · contact PI
Clinical Trials with Immunotoxins$989,879
ZIA · FY2013 · CA · contact PI
Growth Regulation Section$65,991
ZIA · FY2013 · CA · contact PI
Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies$2,527,492
ZIA · FY2012 · CA · contact PI
Clinical Trials with Immunotoxins$1,166,535
ZIA · FY2012 · CA · contact PI
Growth Regulation Section$194,423
ZIA · FY2012 · CA · contact PI
Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies$1,901,616
ZIA · FY2011 · CA · contact PI
Clinical Trials with Immunotoxins$1,086,638
ZIA · FY2011 · CA · contact PI
Growth Regulation Section$892,595
ZIA · FY2011 · CA · contact PI
Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies$2,248,840
ZIA · FY2010 · CA · contact PI
Clinical Trials with Immunotoxins$1,230,498
ZIA · FY2010 · CA · contact PI
Growth Regulation Section$763,757
ZIA · FY2010 · CA · contact PI
Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies$2,131,560
ZIA · FY2009 · CA · contact PI
Clinical Trials with Immunotoxins$860,104
ZIA · FY2009 · CA · contact PI
Growth Regulation Section$747,916
ZIA · FY2009 · CA · contact PI
Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies$1,710,990
Z01 · FY2008 · CA · contact PI
Clinical Trials with Immunotoxins$1,026,594
Z01 · FY2008 · CA · contact PI
Growth Regulation Section$684,396
Z01 · FY2008 · CA · contact PI
Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies$1,528,851
Z01 · FY2007 · CA · contact PI
Gene Discovery$1,418,774
Z01 · FY2007 · CA · contact PI
Clinical Trials with Immunotoxins$819,464
Z01 · FY2007 · CA · contact PI
Immunotoxin Therapy of Solid and Hematopoietic Tumors: P$0
Z01 · FY2006 · BC · contact PI
Gene Discovery$0
Z01 · FY2006 · BC · contact PI
Clinical Trials with Immunotoxins$0
Z01 · FY2006 · BC · contact PI
Clinical Trials with Immunotoxins$0
Z01 · FY2005 · BC
Immunotoxin Therapy of Solid and Hematopoietic Tumors: P$0
Z01 · FY2005 · BC
Gene Discovery$0
Z01 · FY2005 · BC
Gene Discovery$0
Z01 · FY2004 · BC
Regulation of EGFR Gene Activity$0
Z01 · FY2004 · BC
Clinical Trials with Immunotoxins$0
Z01 · FY2004 · BC
Immunotoxin Therapy of Solid and Hematopoietic Tumors$0
Z01 · FY2004 · BC
Immunotoxin Therapy of Solid and Hematopoietic Tumors$0
Z01 · FY2003 · BC
Gene Discovery$0
Z01 · FY2003 · BC
Clinical Trials with Immunotoxins$0
Z01 · FY2003 · BC
Raiolabelled Therapy of Solid Tumors$0
Z01 · FY2002 · BC
Immunotoxin Therapy of Solid and Hematopoietic Tumors: P$0
Z01 · FY2002 · BC
Clinical Trials with Immunotoxins$0
Z01 · FY2002 · BC
Gene Discovery$0
Z01 · FY2002 · BC
Regulation of Cancer Cell Growth and Behavior$0
Z01 · FY2002 · BC
Immunotoxin Therapy in Cancer$0
Z01 · FY2001 · BC
Radiolabelled Therapy of Solid Tumors$0
Z01 · FY2001 · BC
Clinical Trials with Immunotoxins$0
Z01 · FY2001 · BC
Regulation of Cancer Cell Growth and Behavior$0
Z01 · FY2001 · BC
Gene Discovery$0
Z01 · FY2001 · BC
Genetic Analysis of Multidrug Resistance in Tumor Cells$0
Z01 · FY2001 · BC
Regulation of Cancer Cell Growth and Behavior$0
Z01 · FY2000 · BC
Clinical Trials with Immunotoxins$0
Z01 · FY2000 · BC
RADIOLABELLED THERAPY OF SOLID TUMORS$0
Z01 · FY2000 · BC
Immunotoxin Therapy of Solid and Hematopoietic Tumors: Preclinical Studies$0
Z01 · FY2000 · BC
Genetic Analysis of the Multidrug Resistance Phenotype in Tumor Cells (Ira Pasta$0
Z01 · FY2000 · BC
Gene Discovery$0
Z01 · FY2000 · BC